These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 15280679)

  • 1. Epstein-Barr virus primary mismatching and HLA matching: key risk factors for post lung transplant lymphoproliferative disease.
    Wong JY; Tait B; Levvey B; Griffiths A; Esmore DS; Snell GI; Williams TJ; Kotsimbos TC
    Transplantation; 2004 Jul; 78(2):205-10. PubMed ID: 15280679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Posttransplant Lymphoproliferative Disorders in Epstein-Barr Virus Donor Positive/Recipient Negative Lung Transplant Recipients.
    Courtwright AM; Burkett P; Divo M; Keller S; Rosas IO; Trindade A; Mody GN; Singh SK; El-Chemaly S; Camp PC; Goldberg HJ; Mallidi HR
    Ann Thorac Surg; 2018 Feb; 105(2):441-447. PubMed ID: 29223419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary Epstein-Barr virus infection, seroconversion, and post-transplant lymphoproliferative disorder in seronegative renal allograft recipients: a prospective cohort study.
    Hosseini-Moghaddam SM; Alhomayeed B; Soliman N; Weir MA; House AA
    Transpl Infect Dis; 2016 Jun; 18(3):423-30. PubMed ID: 27016725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence, Risk Factors, Clinical Management, and Outcomes of Posttransplant Lymphoproliferative Disorder in Kidney Transplant Recipients.
    Liu M; Husain S; Famure O; Li Y; Kim SJ
    Prog Transplant; 2019 Jun; 29(2):185-193. PubMed ID: 30845885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder after lung transplantation.
    Montone KT; Litzky LA; Wurster A; Kaiser L; Bavaria J; Kotloff R; Palevsky H; Pietra GG; Tomaszewski JE
    Surgery; 1996 May; 119(5):544-51. PubMed ID: 8619211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Post-transplantation lymphoproliferative disorder in the Epstein-Barr virus-naïve lung transplant recipient.
    Aris RM; Maia DM; Neuringer IP; Gott K; Kiley S; Gertis K; Handy J
    Am J Respir Crit Care Med; 1996 Dec; 154(6 Pt 1):1712-7. PubMed ID: 8970360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Post-transplant lymphoproliferative disease in lung transplantation: A nested case-control study.
    Leyssens A; Dierickx D; Verbeken EK; Tousseyn T; Verleden SE; Vanaudenaerde BM; Dupont LJ; Yserbyt J; Verleden GM; Van Raemdonck DE; Vos R
    Clin Transplant; 2017 Jul; 31(7):. PubMed ID: 28383790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Case Report: Non-negligible Epstein-Barr virus-associated posttransplant lymphoproliferative disorders in a lung transplant recipient.
    Hu J; Yu YW; Han DS; Li XJ; Zhang YQ; Cai HL; Xiao YH; Zheng X
    Front Immunol; 2023; 14():1244534. PubMed ID: 37781359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Significance of Epstein-Barr virus status and post-transplant lymphoproliferative disease in pediatric thoracic transplantation.
    Harwood JS; Gould FK; McMaster A; Hamilton JR; Corris PA; Hasan A; Gennery AR; Dark JH
    Pediatr Transplant; 1999 May; 3(2):100-3. PubMed ID: 10389130
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of HLA mismatch, splenectomy and recipient Epstein-Barr virus seronegativity as risk factors in post-transplant lymphoproliferative disorder following allogeneic hematopoietic stem cell transplantation.
    Sundin M; Le Blanc K; Ringdén O; Barkholt L; Omazic B; Lergin C; Levitsky V; Remberger M
    Haematologica; 2006 Aug; 91(8):1059-67. PubMed ID: 16885046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention and preemptive therapy of postransplant lymphoproliferative disease in pediatric liver recipients.
    McDiarmid SV; Jordan S; Kim GS; Toyoda M; Goss JA; Vargas JH; Martín MG; Bahar R; Maxfield AL; Ament ME; Busuttil RW
    Transplantation; 1998 Dec; 66(12):1604-11. PubMed ID: 9884246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Epstein-Barr virus donor and recipient serostatus on the incidence of post-transplant lymphoproliferative disorder in kidney transplant recipients.
    Sampaio MS; Cho YW; Shah T; Bunnapradist S; Hutchinson IV
    Nephrol Dial Transplant; 2012 Jul; 27(7):2971-9. PubMed ID: 22273720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of immunosuppressive maintenance regimens with posttransplant lymphoproliferative disorder in kidney transplant recipients.
    Sampaio MS; Cho YW; Shah T; Bunnapradist S; Hutchinson IV
    Transplantation; 2012 Jan; 93(1):73-81. PubMed ID: 22129761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Post-transplant lymphoproliferative disorders and Epstein-Barr virus DNAemia in a cohort of lung transplant recipients.
    Baldanti F; Rognoni V; Cascina A; Oggionni T; Tinelli C; Meloni F
    Virol J; 2011 Sep; 8():421. PubMed ID: 21892950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A low incidence of posttransplant lymphoproliferative disorder in 109 lung transplant recipients.
    Levine SM; Angel L; Anzueto A; Susanto I; Peters JI; Sako EY; Bryan CL
    Chest; 1999 Nov; 116(5):1273-7. PubMed ID: 10559086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early signs and risk factors for the increased incidence of Epstein-Barr virus-related posttransplant lymphoproliferative diseases in pediatric liver transplant recipients treated with tacrolimus.
    Sokal EM; Antunes H; Beguin C; Bodeus M; Wallemacq P; de Ville de Goyet J; Reding R; Janssen M; Buts JP; Otte JB
    Transplantation; 1997 Nov; 64(10):1438-42. PubMed ID: 9392308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epstein-Barr virus-DNA load monitoring late after lung transplantation: a surrogate marker of the degree of immunosuppression and a safe guide to reduce immunosuppression.
    Bakker NA; Verschuuren EA; Erasmus ME; Hepkema BG; Veeger NJ; Kallenberg CG; van der Bij W
    Transplantation; 2007 Feb; 83(4):433-8. PubMed ID: 17318076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-viral prophylaxis reduces the incidence of lymphoproliferative disease in lung transplant recipients.
    Malouf MA; Chhajed PN; Hopkins P; Plit M; Turner J; Glanville AR
    J Heart Lung Transplant; 2002 May; 21(5):547-54. PubMed ID: 11983544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Posttransplant lymphoproliferative disorders in lung transplant recipients: clinical experience at a single center.
    Angel LF; Cai TH; Sako EY; Levine SM
    Ann Transplant; 2000; 5(3):26-30. PubMed ID: 11147026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human leukocyte antigen type and posttransplant lymphoproliferative disorder.
    Lustberg ME; Pelletier RP; Porcu P; Martin SI; Quinion CD; Geyer SM; Caligiuri MA; Baiocchi RA
    Transplantation; 2015 Jun; 99(6):1220-5. PubMed ID: 25427163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.